Mycophenolate Mofetil Accord (Mycophenolate Mofetil)

The drug is converted in the body to mycophenolic acid, which selectively blocks the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition limits the synthesis of guanosine nucleotides, a critical building block for DNA replication in activated T and B lymphocytes, thereby reducing their proliferation and overall immune response.

The specific dose of Mycophenolate Mofetil Accord is determined by the prescribing clinician based on the individual’s medical condition, transplant type, renal function, and other factors. Patients should follow the dosage instructions provided by their healthcare professional and not adjust the dose without medical guidance.

Mycophenolate Mofetil is classified as pregnancy category X, indicating it can cause fetal harm and is contraindicated during pregnancy. It is also not recommended while breastfeeding because it may be excreted in breast milk and affect the infant. Effective contraception is required for both male and female patients of reproductive potential.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, Mycophenolate Mofetil offers a different mechanism—targeting lymphocyte proliferation rather than cytokine production. It is often used in combination regimens to achieve synergistic immunosuppression while potentially reducing the dose‑related toxicities associated with each individual agent.

Store the product at room temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not refrigerate or freeze unless the manufacturer’s labeling specifically indicates otherwise.

Mycophenolate Mofetil Accord is taken orally, usually with food or a glass of water to improve tolerability. The exact administration schedule—such as once or twice daily—depends on the prescribing clinician’s instructions and the therapeutic regimen chosen for the patient.

Serious adverse events include bone‑marrow suppression (leading to leukopenia, anemia, or thrombocytopenia), severe opportunistic infections, and liver toxicity. Patients should be monitored regularly with blood counts and liver function tests, and any signs of infection or abnormal labs should be reported promptly to a healthcare professional.

The drug is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate or its components, and patients with severe uncontrolled infections. Caution is also advised for those with significant renal or hepatic impairment, and it should be avoided in patients receiving live vaccines.